INTRODUCTION
In Japan, recent smoking rate of the women is 8.2% [1] and women in Hokkaido prefecture, northernmost of Japan, have the highest that rates (16.4%) in Japan [2] .
Although previous studies show adverse effects of maternal smoking during pregnancy, there are few studies examining genetic susceptibility of smokers on birth outcomes.
Tobacco smoke is a mixture of more than 4,000 chemicals, e.g., polycyclic aromatic hydrocarbons (PAHs), N-nitrosamines, benzene, and acetaldehyde. Many of these compounds are carcinogenic, and their metabolites can form DNA adducts [3] [4] [5] . In previous studies, maternal smoking during pregnancy was associated with adverse pregnancy outcomes, i.e., miscarriage, stillbirth, and low birth weight [6] [7] [8] .
Associations between maternal genetic polymorphisms of PAH-and N-nitrosamine-metabolizing enzymes and/or prenatal smoking and infant birth size have been investigated in epidemiological studies [9] [10] [11] [12] [13] [14] . However, only three reports examined combinations of maternal genetic polymorphisms in PAH-metabolizing enzymes and active or passive smoking during pregnancy on birth size [11, [15] [16] .
Xenobiotic metabolism can be classified as phase I (metabolism) and phase II (conjugation reaction). The aromatic hydrocarbon receptor (AHR), the cytochrome P450s (CYP) 1A1, 1A2, and 1B1, and the glutathione S-transferases (GST) M1 and T1 serve as Phase I and Phase II enzymes for such PAHs as benzo [a] pyrene (BP), benzo [a] anthracene, and dioxins contained in tobacco smoke [17] [18] [19] [20] . The X-ray-complementing repair 1 protein (XRCC1) eliminates the adducts formed by the BP metabolite BP-7.8-diol oxide (BPDE) and DNA [21] [22] . Recent studies reported that the AHR-GG (G>A, Arg554Lys; dbSNP ID, rs2066853), CYP1A1-AG/GG (A>G, Ile462Val; dbSNP ID, rs1048943), GSTM1 -and GSTT1 -genotypes are associated with reduced birth size when the fetus had been exposed to active or passive smoking by the mother [9] [10] [11] [13] [14] [15] [16] . The CYP1A2 (A>C, CYP1A2*1F; dbSNP ID, rs762551)
genotype has greater enzyme activity in the presence of an inducer, e.g., smoking, caffeine intake, and/or theophylline intake in vitro and in vivo [23] [24] [25] . Smoking has been associated with a decrease in the catalytic activity of CYP1B1-CC (C>G, Leu432Val; dbSNP ID, rs1056836) for such substrates as 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine [26] . The XRCC1 (C>T, Arg194Trp; dbSNP ID, rs1799782; G>A, Arg399Gln; dbSNP ID, rs25487) genotypes alter XRCC1 expression in vitro [21, 27] . However, associations between maternal CYP1A2, CYP1B1,
and XRCC1 polymorphisms and smoking on reduced infant birth size have not been examined. Some studies have shown that associations between maternal genetic polymorphisms of PAH-metabolizing enzymes, prenatal smoking, and infant birth size, but these studies were limited to a small sample size and did not consider various combinations of genotypes. Infant birth size may be further reduced by polymorphic genes encoding metabolizing enzymes and DNA repair proteins. We hypothesized that PAH-metabolizing and DNA repair proteins could affect infant birth size by mediating maternal susceptibility to smoking in pregnant Japanese women. Therefore, the aim of this study was to investigate maternal genetic polymorphisms that might affect passive or active smoking by pregnant Japanese women-with smoking/non-smoking defined by the plasma levels of the biomarker cotinine-on infant birth size. We characterized genetic susceptibility using maternal genotypes of AHR, CYP1A1, CYP1A2, CYP1B1, GSTM1, GSTT1, and XRCC1 individually and in combination.
METHODS

Questionnaire and medical records
Participants completed a questionnaire during their first trimester of pregnancy that included maternal and paternal information related to age, pre-pregnancy height and weight, previous medical history, educational level, household income, alcohol status, parity, housemates who smoked, job category, and exposure to smoking on the job. We obtained gestational age, infant gender, singleton or twin birth, and the maternal medical history during pregnancy from the subjects' medical records at the time of birth. We asked the mothers to report the birth weight, length, and head circumference in a maternity passbook attached to the questionnaire. In addition, when the child was 4 months old, information about smoking status during the pregnancy was obtained through the following questions: "Did you (or your partner) smoke during your pregnancy?". If the answer was yes, "How many cigarettes did you (or your partner) smoke per day?" If the mother had quit smoking during her pregnancy, we asked when did she quit. We also asked how many cigarettes the mother smoked per week. We defined smoking in the third trimester based on the questionnaire.
Third-trimester plasma cotinine measurement
Because of strong influence of maternal smoking at the third trimester of pregnancy on reduced birth size [28] , we measured the plasma cotinine concentration of the pregnant women during their third trimester (at 8th months of pregnancy) using a very sensitive enzyme-linked immunosorbent assay (ELISA) [29] performed at Cosmic Corporation, Tokyo, Japan. Detection limit of plasma cotinine level was 0.12 ng/mL [29] . A mother was considered to be a non-smoker if her cotinine level was ≤11.48 ng/mL and a smoker if her cotinine level was ≥11.49 ng/mL. In addition, a mother was considered to be a passive smoker if her cotinine level was between 0.22 and 11.48 ng/mL and a passive, non-smoker if her level was <0.21 ng/mL [29] . These cut-off values are based on a previous study [29] .
Genotype measurements
Maternal blood samples were collected on giving birth, and 200-400 μg of the sample was used to extract genomic DNA from 3,263 subjects. The QIAamp DNA Blood Mini Kit (QIAGEN GmbH, Hilden, Germany) [30] and Maxwell 16 DNA Purification Kit (Promega, Madison, WI, USA) were isolate and purify DNA according to the manufacturer's instruction. AHR, CYP1A1, CYP1A2, CYP1B1, GSTM1 (+/-), and GSTT1 (+/-) polymorphisms were determined by the TaqMan PCR method as described [11, [31] [32] [33] [34] [35] . XRCC1 genotyping was performed using a 7300/7500 Real-Time PCR AmpErase UNG (Applied Biosystems) in a total volume of 10 µL. Reaction conditions were 10 min at 95°C, followed by 40 cycles at 92°C for 15 s and at 60°C for 1 min.
Allelic discrimination was determined by the fluorescence of the two dyes at 60°C. We randomly selected 15 samples (the successfully genotyped samples) and repeated genotyping to check for genotyping quality for each of genetic polymorphisms. The results were 100% concordant.
Selection of participants
The study participants were Japanese mother-child pairs drawn from the birth cohort of The Hokkaido Study on Environmental and Children's Health begun in February 2003 [36] [37] . The study protocol has been described [36] [37] . In brief, this is a prospective ongoing birth cohort study. All Japanese pregnant women who presented at any of the participating healthcare facilities for prenatal care during the first trimester were considered eligible for the study. Those who agreed to participate in the study were contacted and recruited at 37 gynecological hospitals and clinics within Hokkaido, the northernmost prefecture in Japan. Data were generated from these participants by means of baseline questionnaires, biochemical assays, birth records, and four-month 4-month postpartum questionnaires. To date, there have been only three reports on the association between prenatal smoking, maternal genetic polymorphisms, and infant birth size [8, 12, 38] . Figure 1 shows the flow diagram for the participants in this study. subjects considered as smokers.
Statistical methods
When we compared data acquired for non-smokers versus data for smokers, the Mann-Whitney U-test was used as a non-parametric test for two continuous variables, and the χ 2 test was used as the statistical test for two categorical variables. The response variables were infant birth weight, birth length, and birth head circumference. The independent variables were (i) maternal genotype, (ii) maternal smoking status, (iii) one categorical variable that was the combination of maternal genotype and smoking status, and (iv) one categorical variable that was the combination of two or three genotypes and smoking status. Multiple linear regression models were used to evaluate the interrelationship between independent variables and response variables, while adjusting for the following covariates: maternal age (years), height (cm), weight before pregnancy (kg), parity (primiparous or multiparous), alcohol status during the first trimester (yes or no), educational level (junior high school, senior high school, college, or university), annual household income (<3, 3 to <5, 5 to <8, or ≥8 million yen), infant gender, and gestational age (weeks) [40] [41] [42] [43] . The data were examined in the following steps. We used a multiple linear regression model to examine the association of each maternal demographical variable (infant gender, gestational age, maternal age, height, weight before pregnancy, parity, alcohol intake during the first trimester, education level and annual household income) and genotype and infant birth size adjusted for potential confounders identified in a previous study. Next, we used a multiple linear regression model to examine the association of combined maternal smoking and genotype and infant birth size for nine potential confounders. Third, we used a multiple linear regression model to examine the association of combined maternal smoking and all combinations of three genotypes with infant birth size. We treated "low-risk" genotypes
XRCC1-CC (C>T, Arg194Trp
) and XRCC1-GG (G>A, Arg399Gln)] as references for the multiple linear regression analyses. We tested the effects caused by the gene and smoking interaction terms (e.g., AHR × smoking; AHR × CYP1A1 × smoking; AHR × CYP1A1 × XRCC1 × smoking). The interaction P-value (P int ) was calculated using a post-estimation combined F-test for the two interaction variables, namely maternal genotypes and smoking. A P-value < 0.05 was considered significant, and Bonferroni corrections were used for multiple comparisons.
Ethics
This study was conducted with the written, informed consent of all participants. The
Institutional Ethical Board for Human Gene and Genome Studies of Hokkaido
University Graduate School of Medicine approved the study protocol. The guidelines of the Declaration of Helsinki were followed. Table 1 shows the characteristics in relation to their prenatal smoking status.
RESULTS
Compared with infants to born to non-smokers, infants born to smokers had a mean lower birth weight (3,081 g versus 3,002 g; P < 0. cm; 95% CI, -0.94, -0.13). We did not find any significant P int (data not shown).
DISCUSSION
To the best of our knowledge, our study is the first to clearly show an association with XRCC1 (C>T, Arg194Trp) of DNA repair genotypes and third-trimester maternal smoking-as defined by the maternal cotinine plasma levels-and infant birth size. Our most important finding is that infants born to smokers combined with AHR-GG, CYP1A1-AG/GG, and XRCC1-CT/TT genotypes are significantly more likely to have a reduced birth size compared with infants born to non-smokers carrying one of the AHR-GA/AA, CYP1A1-AA and XRCC1-CC genotypes. This result is consistent with those of previous studies, which suggested that infants born to mothers smokers with
AHR-GG and CYP1A1-AG/GG compared to infants born to non-smokers with
AHR-GA/AA and CYP1A1-AA genotypes suffered a greater adverse effect on their growth in utero [9, 11] .
The genotypes AHR-GG, CYP1A1-AG/GG, CYP1A2-AC/CC,
and CYP1B1-CG/GG correlate with an increase in the metabolic activities and expression of their protein products, and XRCC1-CT/TT correlates with a decrease in its protein product's DNA repair activity in comparison with their referent genotypes [23, [44] [45] [46] [47] [48] . GSTM1 and GSTT1 are detoxifying enzymes [49] . Infants born to smokers during pregnancy and had specific AHR, CYP1A1, CYP1A2, GSTM1, and XRCC1
genotypes, but not those with CYP1B1 and GSTT1, had a reduced birth weight of 56-62 g in comparison with infants born to non-smokers and had the referent genotypes 
CYP1A1-AA, and XRCC1-CC, those of infants born to non-smokers with AHR-GG, CYP1A1-AG/GG, and XRCC1-CT/TT
were 97 g heavier. However, infants born to smokers with "high-risk" genotypes of the same genes were 145 g lighter than those from non-smokers carrying the "low-risk" genotypes. Our first hypothesis is that the "high-risk" genotypes AHR-GG and CYP1A1-AG/GG produce more BPDE metabolites and thus require more detoxification of BPDE compared with the reference genotypes.
Non-smokers carrying the "high-risk" genotypes promote this route to detoxify BPDE, and thus their infants might have greater birth weight than non-smokers carrying the "low-risk" genotypes. Our secondary hypothesis is that the "high-risk" genotype of XRCC1 (C>T)-CT/TT produces more was BPDE-DNA adducts and compromised DNA repair than the reference genotype. Smoking combined with "high-risk" genotypes promotes conversion of PAH to BPDE-DNA adducts and therefore produces infants with lower birth weight than non-smoking combined with "low-risk" genotypes. We cannot ignore that third-trimester maternal smoking may be more damaging to infant birth size when mothers have AHR-GG, CYP1A1-AG/GG, and XRCC1-CT/TT.
Compared with infants born to mothers with AHR-GA/AA who did not smoke, infants born to mothers with AHR-GA/AA who smoked were shown in our previous study to have a 211 g decrease in birth weight [11] , whereas in this study we found 56 g decrease in birth weight. The key difference between the results of the two studies may be the definition of third-trimester maternal smoking. The different maternal smoking definitions and different numbers of female infants born to mothers who smoked (61.6% [11] vs. 48.5% (this study)) may have affected the birth weight results.
In this study, 1,759 mothers reported no smoking during the third trimester of pregnancy, however 157 of them had cotinine levels ≥11.49 ng/mL and considered as smokers. Given that 1,265 mothers had cotinine levels ≥11.49 ng/mL, the percentage of mothers who claimed that they did not smoke yet had cotinine levels ≥11.49 ng/mL was 12.4% (= 157 out of 1,265). Mothers who smoked during the third trimester more often had partners who smoked than did mothers who did not smoke (Table 1) . Possibly, mothers who claimed to be non-smokers yet had high cotinine levels were not truthfully reporting their smoking status as shown in previous studies [53] [54] or were strongly exposed to the smoke of partners, housemates, and/or co-workers. A total of 692 mothers reported smoking during their third trimester; of those 37 mothers had cotinine levels ≤11.48 ng/mL and categorized as non-smokers in this study (Table 2 ). A total of 1,998 mothers had cotinine levels ≤11.48 ng/mL. Therefore, the percentage of mothers who smoked but considered non-smokers based on their cotinine levels was 1.9% (= 37 out of 1,998). Possible, the reason for the unexpectedly low plasma cotinine levels in mothers who claimed to smoke was that they smoked only occasionally, which caused their typical cotinine levels to be underestimated at the time of measurement as found in previous studies [55] [56] . We conclude that measurement of cotinine levels is a more accurate assessment than allowing the mothers to self-report their third-trimester smoking status.
The strengths of this study are as follows. First, we accurately defined third-trimester maternal smoking status by measuring plasma cotinine levels. There may be a risk of circle conclusion, and it is unsure what the use of plasma cotinine level, instead of self-reported smoking status. Second, we correlated reduction in birth size for infants born to mothers who smoked with polymorphisms in genes encoding a PAH receptor, PAH metabolic and detoxification enzymes, and a DNA repair enzyme. In particular, we assessed the effects of combinations of these polymorphisms. However, we only measured the cotinine levels of the mothers a single time in the limitation of this study. Cotinine has a short biological half-life of 17.9 hours [57] . However, by categorizing mothers as smokers or non-smokers based on cotinine level, we seem to have accurately identified the mothers (94.6% accuracy, with 692 mothers self-reporting as smokers with 655 having cotinine levels ≥11.49 ng/mL, and 91.1% accuracy, with 1,759 mothers self-reporting as non-smokers with 1,602 having cotinine levels ≤11.48 ng/mL (Table 2) ). A second limitation is that the comparison of birth size of infants born to non-smokers and smokers was not adjusted for the other maternal genetic polymorphisms, such as those of secretor gene fucosyltransferase (FUT) 2, maternally expressed imprinted gene H19, and epidermal growth factor (EFG) genes, that are known to be associated with birth weight [58] [59] [60] . Therefore, the results obtained here may be affected by individual genetic factors, such as genetic polymorphisms, not examined in this study.
CONCLUSIONS
We show that the correlation between third-trimester maternal smoking-as defined by the maternal plasma cotinine levels-and a reduced size of their infants is affected by specific combinations of AHR, CYP1A1, and XRCC1 polymorphisms. We must still evaluate the exposure of infants to toxic substances in cigarette smoke after birth.
Animal studies have found that active and/or passive smoking during pregnancy affects numerous immune functions and endocrine systems [61] [62] [63] [64] . Little research has been conducted on the effects of passive maternal smoking in conjunction with maternal or infant genetic factors. In the future, we will investigate if passive maternal smoking-as affected by maternal genetic factors such as a combination of AHR, CYP1A1, and Multiple linear regression models adjusted for maternal age, height, weight before pregnancy, parity, alcohol intake during pregnancy, maternal education level, annual household income, gestational age and infant gender. *; Statistically significant decreased birth weight for infants of smokers compared with reference (P < 0.05). Multiple linear regression models adjusted for maternal age, height, weight before pregnancy, parity, alcohol intake during pregnancy, maternal education level, annual household income, gestational age and infant gender. *; Statistically significant decreased birth length for infants of smokers compared with reference (P < 0.05). Multiple linear regression models adjusted for maternal age, height, weight before pregnancy, parity, alcohol intake during pregnancy, maternal education level, annual household income, gestational age and infant gender. *; Statistically significant decreased birth head circumference for infants of smokers compared with reference (P < 0.05). 
